New drug duo shows promise against lung cancer in early trial
NCT ID NCT03563716
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested whether adding tiragolumab to the standard immunotherapy atezolizumab helps people with advanced non-small cell lung cancer who have not had chemotherapy. 135 participants received either the combination or a placebo plus atezolizumab. The main goals were to see if tumors shrank and how long they stayed under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tiragolumab and atezolizumab (immunotherapy drugs)
What this could lead to
If successful, this combination could offer a new first-line immunotherapy option for people with advanced non-small cell lung cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong
This is a phase 2 trial with only 135 participants, so results are preliminary. The combination may not prove more effective than existing treatments, and immune-related side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona Oncology Associates, PC - HAL
Tempe, Arizona, 85284, United States
-
Asan Medical Center
Seoul, 05505, South Korea
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centro Medico Quironsalud Sagrado Corazon
Seville, 41013, Spain
-
Chang Gung Memorial Hospital - Linkou
Taoyuan, 333, Taiwan
-
Chungbuk National University Hospital
Cheongju-si, 28644, South Korea
-
Clinica Universitaria Navarra (Madrid)
Madrid, 28036, Spain
-
Clinical Center of Serbia
Belgrade, 11000, Serbia
-
Clinical Hospital Center Bezanijska Kosa
Belgrade, 11070, Serbia
-
Complejo Hospitalario Universitario Insular?Materno Infantil
Las Palmas de Gran Canaria, LAS Palmas, 35016, Spain
-
Florida Cancer Specialists - NORTH - SCRI - PPDS
St. Petersburg, Florida, 33705, United States
-
Hopital Nord AP-HM
Marseille, 13015, France
-
Hospital General Universitario de Alicante
Alicante, 03010, Spain
-
Hospital Regional Universitario de Malaga ? Hospital General
Málaga, 29010, Spain
-
Hospital Univ Germans Trias i Pujol
Badalona, Barcelona, 8916, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Puerta de Hierro - Majadahonda
Madrid, 28222, Spain
-
Hospital Universitario Vall d'Hebron - PPDS
Barcelona, 08035, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
ICO Paul Papin
Angers, 49055, France
-
Illinois Cancer Care
Peoria, Illinois, 61615, United States
-
Illinois Cancer Specialists
Arlington Heights, Illinois, 60005, United States
-
Institut Bergonié Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest
Bordeaux, 33076, France
-
Institut De Cancerologie De L'Ouest
Saint-Herblain, 44115, France
-
Institute of Lung Diseases Vojvodina
Kamenitz, Južnobanatski Okrug, 21204, Serbia
-
Kangbuk Samsung Hospital
Seoul, 03181, South Korea
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
National Cheng Kung University Hospital
North Dist., 70403, Taiwan
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Northwest Cancer Specialists - Vancouver
Vancouver, Washington, 98684, United States
-
Research Medical Center
Kansas City, Missouri, 64132, United States
-
SCRI Florida Cancer Specialists South
Fort Myers, Florida, 33901, United States
-
SCRI Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Seoul National University Bundang Hospital
Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Taipei Medical University ?Shuang Ho Hospital
New Taipei City, 23561, Taiwan
-
Taipei Veterans General Hospital
Taipei, 1121, Taiwan
-
University of Kansas Medical Center
Westwood, Kansas, 66205, United States
-
Virginia Cancer Specialists, PC
Fairfax, Virginia, 22031, United States